Early Failure Is Like Yeast: Early Triage Boosts Big Pharma's R&D Productivity - Tufts
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
One of the strengths of the big pharma R&D model is the ability to triage candidates early in development, a recent study of R&D productivity at the top 50 pharmaceutical firms by the Tufts Center for the Study of Drug Development suggests.